To raise awareness of the value of water and the impact of the global water crisis on community health, education and economics, the Caterpillar Foundation, together with its global partners, today launched the Value of Water campaign. The Caterpillar Foundation, the philanthropic arm of Caterpillar Inc. (NYSE: CAT), is on a mission to empower 50 million people around the world to rise out of extreme poverty by 2020.
The Foundation recognizes that water is one of the most critical basic needs of people and their communities – yet, about 844 million people, or 1 in 9, still lack access to clean and safe water. To learn more about the Value of Water awareness campaign, read stories of those directly impacted by water issues around the world and find out how to get involved, visit www.togetherstronger.com/year-of-water/.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284451-caterpillar-foundation-value-of-water-campaign/
Susan G. Komen Knoxville readies the finish line for the 2014 Race for the Cure on October 18th at World’s Fair Park.
This year’s “Do You Tutu?” theme will attract a variety of pink tutus to the race. Komen Knoxville launched this theme to bring a sense of hope and happiness to the families, supporters and survivors battling breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7313552-komen-knoxville-laces-up-for-2014-race-for-the-cure-do-you-tutu/
New Orleans is one of the country’s most culturally, architecturally, and musically interesting cities. It will serve as the picturesque backdrop for Team Challenge, the Crohn’s & Colitis Foundation of America’s (CCFA) endurance training and fundraising program, to take over the city on February 28, 2016 for the Rock ‘n’ Roll New Orleans Marathon, Half Marathon & 10k.
For the first time ever, Team Challenge is recruiting for participants to run through the Big Easy while raising critical funds and awareness of Crohn’s disease and ulcerative colitis. Collectively known as inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis are painful, medically incurable diseases that attack the digestive system. There are more than 1.6 million Americans living with these chronic, debilitating diseases.
“Team Challenge provides people with an opportunity to raise critical research dollars while training to do something that, for many people, they never imagined they’d be able to do,” said Craig Comins, vice president of Team Challenge. “It is inspiring to see a group of people come together, some who have these diseases and some who do not, united in the mission of finding a cure for Crohn’s disease and ulcerative colitis.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7512652-ccfa-team-challenge-recruit-nola/
The Epilepsy Foundation launched the “Talk About It!” public service announcement featuring actor Greg Grunberg to raise awareness and encourage open dialogue about epilepsy and seizures. Greg, best known for his roles on Heroes, Alias, and Felicity, has an adult son who lives with epilepsy, a condition that affects nearly 3 million Americans. The Epilepsy Foundation and Greg teamed up for this PSA, sponsored by Sunovion Pharmaceuticals Inc., to drive much needed conversation about epilepsy – bringing the condition out of the shadows and honoring a community that deserves better awareness and understanding. More information about the PSA and initiative can be found by visiting the Epilepsy Foundation at epilepsy.com.
Dentro de las más de 50 propuestas de estudios de investigación, el estudio sobre ácidos grasos de omega 3 en pacientes hospitalizados que requieren nutrición parenteral y presentan complicaciones relacionadas con insuficiencias intestinales propuesto por la investigadora médica, la Dra. Aurora Serralde Zúñiga, ganó el primer subsidio para la investigación sobre nutrición parenteral en América Latina (Parenteral Nutrition Research Grant Latin America).
To view the multimedia release go to:
https://www.multivu.com/players/Spanish/8451051-ganadora-del-subsidio-fresenius-kabi/
Kohler Co., a global leader in kitchen and bath products and power systems, has developed a portable showering experience to assist volunteers following hurricanes and other disasters. The new 42-foot KOHLER Relief trailer, which is powered by a KOHLER mobile generator, has been deployed for the first time by Operation Blessing International (OBI) to New Bern, North Carolina, a community with severe flooding caused by Hurricane Florence. OBl is a global nonprofit humanitarian organization providing aid in 39 countries through disaster relief, health and medical care, hunger relief, and access to safe water.
“We’re pleased to work with Kohler to bring the Relief Trailer to our many dedicated volunteers who are in North Carolina helping those in need following the devastation caused by Hurricane Florence,” said Ronda Sherman, vice president of philanthropy for Operation Blessing International. “Our volunteers are often deployed for weeks or months at a time following these massive storms and having the opportunity to shower onsite will significantly enhance our team’s efforts throughout the cleanup and recovery process.”
Announced today by VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.
What is exposome?
The human body is subjected to and responds to complex exposures throughout the lifespan, including exposures from the environment, diet, lifestyle. For this highly complex interaction, the term exposome was recently coined by Dr. Christopher Wild at the World Health Organization‘s International Agency for Research on Cancer.
The exposome analysis, therefore, complements the human genome by providing a comprehensive description of individuals’ lifelong environmental exposures. Exposome research aims to look at the holistic view of the human body’s exposures, how the body responds to those exposures, and their combined effects.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7751451-vichy-announces-exposome-grant/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Over 35 million Americans who grew up in the free spirited '60s and '70s are finding their sex lives challenged. Whether they are in long term relationships or rediscovering midlife dating, most women over 50 are dealing with vaginal dryness, a common symptom of menopause. Fortunately, baby boomers are finding non-hormonal solutions to help maintain a healthy sex life.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7288651-replens-silky-smooth-lubricant-vaginal-moisturizer/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
